Research programme: ethylenedicysteine glucosamine drug conjugates - CellPoint

Drug Profile

Research programme: ethylenedicysteine glucosamine drug conjugates - CellPoint

Alternative Names: 187 Re ethylenedicysteine glucosamine; 187-Re-EC-G; Platinum ethylenedicysteine glucosamine; Platinum-EC-G; Re-187-EC-G

Latest Information Update: 05 Feb 2014

Price : $50

At a glance

  • Originator CellPoint
  • Class Drug conjugates; Organometallic compounds
  • Mechanism of Action Apoptosis stimulants; DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical B cell lymphoma

Most Recent Events

  • 05 Feb 2014 Preclinical development is ongoing
  • 19 Mar 2013 Preclinical development is ongoing
  • 24 Jan 2012 CellPoint's entire portfolio of products under development licensed to Radiopharmacus in Brazil
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top